Unilife — Q1 FY2015 Earnings Presentation
12 slides from Unilife's earnings presentation, Nov 14, 2014
Slide 1: Earnings Call: First Quarter of Fiscal Year 2015
Exhibit 99.2 Earnings Call First Quarter of Fiscal Year 2015 November 10, 2014 Confidential-Unilife Corporation
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements Thispresentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to our manag
Slide 3: Our Quantum Shift
Our Quantum Shift An aspirational A focused discussion discussion on cornerstone deals • Prospective deals • Executed agreements • Investment in R&D and • Already generating business expansion revenue Confidential-Unilife Corporation
Slide 4: Commercial Supply Agreement with Sanofi
Commercial Supply Agreement with Sanofi 15-Year Master Services and Commercial Supply Agreement Unilife to be the sole provider of wearable injectors for use with all of Sanofi’s applicable large dose volume drugs(excluding insulin) Sanofi has non-exclusive access to Unilife’s wearable injectors Col
Slide 5: Generating Revenue from Sanofi agreement
Generating Revenue from Sanofi agreement Upfront payment Unilife received an upfront payment from Sanofi Customization payments Unilife to receive milestone-based payments to customize its wearable injectors to customer requirements for each applicable drug / indication Each program expected to gene
Slide 6: MedImmune Agreement
MedImmune Agreement The global biologics R&D arm of AstraZeneca Long-term commercial supply agreement Unilife to customize and supply devices from its platform of wearable injectors for use with target MedImmune molecules Several drugs may be selected for use with Unilife's wearable injectors Some d
Slide 7: Supply Agreements for the Unifill platform
Supply Agreements for the Unifill platform Sanofi for Unifill Finesse “The deal with Unilife will bring added value to our customers, reinforcing the safety aspects of a performing device looking at reducing the risk of needlestick injuries. Sanofi has kept evolving with cutting edge technology for
Slide 8: Incremental Growth
Incremental Growth A Large, Rapidly Growing Commercial Pipeline Commercial Supply Contracts - Sanofi (wearable injectors) - Medimmune (wearable injectors) - Sanofi (Unifill Finesse) - Hikma (Unifill, Nexus, Allure) Active Customer Programs - 15 (up from 12 last quarter) Commercial Pipeline - Multipl
Slide 9: Scaling Up Manufacturing Capacity
Scaling Up Manufacturing Capacity Figure 1 –Segments of the Manufacturing Process for Wearable Injector Primary Drug Containers Figure 2 –Wearable Injector Primary Drug Containers and Integrated Fluid Path Figure 3 –Demonstration of Unilife products being filled 9 Confidential-Unilife Corporation
Slide 10: Increasing Revenue. Narrowing our Loss.
Increasing Revenue. Narrowing our Loss. Continue to strengthen revenue outlook for FY15 and beyond Initial commercial sales commenced, and expected to accelerate Increasing number of active customer programs supports increased revenue from upfront fees and milestone-based customization payments On t
Slide 11: Questions
Questions November 10, 2014 11 Confidential-Unilife Corporation
Slide 12: Final Comments
Final Comments November 10, 2014 Confidential-Unilife Corporation